Drug Profile
Influenza virus H9N2 vaccine - Johnson & Johnson Innovative Medicine
Latest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Crucell
- Class Influenza A vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H9N2 subtype
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 03 Dec 2012 Janssen licenses the NanoPass MicronJet®, microneedle delivery device for use in its vaccine programmes
- 14 Aug 2007 Crucell completes a phase I/II trial in the UK